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Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic fat
accumulation in the absence of significant ethanol consumption, viral
infection, or other specific causes of liver disease. Currently the most
common chronic liver disease, affecting 30% of the Western world,
NAFLD may progress to cirrhosis and end-stage liver disease and may
increase the risk of developing diabetes and cardiovascular disease. Al-
though its pathogenesis is unclear, NAFLD is tightly associated with in-
sulin resistance and the metabolic syndrome. No established treatment
exists, and current research is targeting new molecular mechanisms that
underlie NAFLD and associated cardiometabolic disorders. This review
discusses some of these emerging molecular mechanisms and their ther-
apeutic implications for the treatment of NAFLD: microRNAs, incretin
analogs/antagonists, liver-specific thyromimetics, AMP-activated pro-
tein kinase activators, and nuclear receptors farnesoid X receptor and
pregane X receptor.
375
A
nn
u.
 R
ev
. M
ed
. 2
01
0.
61
:3
75
-3
92
. D
ow
nl
oa
de
d 
fro
m
 ar
jou
rna
ls.
an
nu
alr
ev
iew
s.o
rg
by
 U
ni
ve
rs
ita
 d
eg
li 
St
ud
i D
i T
or
in
o 
- D
ep
ar
tm
en
t o
f P
la
nt
 B
io
lo
gy
 o
n 
02
/0
9/
10
. F
or
 p
er
so
na
l u
se
 o
nl
y.
AREV402-ME61-25 ARI 6 December 2009 8:29
NAFLD:
nonalcoholic fatty liver
disease
NASH: nonalcoholic
steatohepatitis
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is
characterized by hepatic fat accumulation in the
absence of significant ethanol consumption, vi-
ral infection, or other specific causes of liver dis-
ease. Currently the most common chronic liver
disease in the world, NAFLD affects 30% of the
Western adult population (1) and encompasses
a spectrum of histological severity ranging from
simple steatosis to nonalcoholic steatohepati-
tis (NASH), the latter progressing to cirrhosis
in 10%–25% of cases over 8–10 years (2). Al-
though its pathogenesis is unclear, NAFLD is
tightly associated with overall and central adi-
posity, insulin resistance, metabolic syndrome,
and type 2 diabetes mellitus.
MICRORNA BIOGENESIS AND REGULATORY
FUNCTION
MiRNAs are initially transcribed by RNA polymerase II or III
in the nucleus to form large pri-miRNA transcripts, which may
be several hundred or thousands of nucleotides long, and are
capped (MGpppG) and polyadenylated. The pri-miRNAs are
processed in the nucleus by the RNase III enzyme Drosha and
by the dsRNA (double-stranded RNA)–binding protein Pasha
(also known as DGCR8), into smaller pre-miRNAs, which fold
into stem-loop hairpin structures. RanGTP and exportin 5 trans-
port the pre-miRNA into the cytoplasm. Subsequently, another
RNase III enzyme, Dicer, processes the pre-miRNA to gener-
ate a transient nucleotide duplex. The duplex is loaded into the
miRNA-associated miRISC (multiprotein RNA-induced silenc-
ing complex), which includes the Argonaute proteins (AGO). One
strand of the miRNA is preferentially retained in this complex and
becomes the mature miRNA; the opposite strand, known as the
passenger strand or miRNA∗, is eliminated from the complex.
Some intronic miRNA precursors can bypass Drosha processing
to produce miRNAs by Dicer, possibly an alternative pathway for
miRNA biogenesis. The mature miRNA binds to complemen-
tary sequences in the 30 untranslated regions (30UTRs) of the
target mRNAs to regulate gene expression in one of two ways:
miRNAs that bind to mRNA targets with imperfect comple-
mentarity block target gene expression via translational silenc-
ing, whereas miRNAs binding their mRNA targets with perfect
complementarity enhance target gene expression.
Currently there is no established treatment
for NAFLD. Weight loss through lifestyle
changes is difficult to achieve and maintain,
and thiazolidinediones (a class of insulin sen-
sitizers), a promising drugs for the treatment of
NAFLD/NASH, pose weight-gain and long-
term safety issues. Therefore, basic research is
exploring new molecular mechanisms to target
for the treatment of NAFLD and associated
disorders.
MICRORNAS AND NAFLD
MicroRNAs (miRNAs) are a large class of ge-
nomically encoded 22-nucleotide-long RNAs
that regulate target mRNAs in plants and an-
imals through an antisense mechanism. Since
the identification of the first miRNA, lin-4, in
the nematode Caenorhabditis elegans (3), investi-
gators have identified 695 miRNAs in humans,
488 in mouse, and 152 in the fly Drosophila
melanogaster (4). It is increasingly understood
that miRNA maturation is complex and highly
modulated, subjecting these small posttran-
scriptional regulators of gene expression them-
selves to extensive posttranscriptional control.
Each miRNA has several target genes, possi-
bly dozens or hundreds, involved in diverse de-
velopmental and cellular processes, including
cellular metabolism proliferation, differentia-
tion, and apoptosis (5). Binding of the target
gene results in modulation of the target mRNA
through mechanisms that have not been fully
elucidated but seem to involve translational re-
pression, deadenylation and degradation of the
target mRNAs (see sidebar MicroRNA Biogen-
esis and Regulatory Function). MicroRNA dys-
regulation has been implicated in various dis-
eases, particularly cancers (6, 7). Accordingly,
much effort has been put into developing pro-
filing methods for miRNA expression patterns
as experimental tools for the biologist and po-
tential diagnostic and therapeutic tools for the
clinician.
In liver diseases, most research on miRNAs
focuses on their role in hepatocarcinogenesis.
Microarray analysis and quantitative real-time
polymerase chain reaction (RT-PCR) disclosed
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Table 1 Dysregulated miRNAs in liver diseases
Disease Dysregulated miRNA Target gene/cellular function
Hepatocarcinoma (+): 10b, 18, 20, 21,
221/222, 224
21: promotes cell invasion, migration, and growth via repression of the tumor
suppressor PTEN
(−): 122, 145, 150, 199a,
199b, 200b, 214, 223
122: suppresses cyclin G1 expression; binds HCV-RNA enhancing its replication
Colangiocarcinoma (+): 21, 23a, 27, 141, 200b 21: promotes gemcitabine resistance
NAFLD (+): 10b, 15b, 21200b 10b: enhances peroxisome proliferator-activated receptor α expression
(−): 107/103, 122, 135a 15b: modulates insulin receptor, insulin-like growth factor 1 receptor, PGC-1α
expression, lipopolysaccharide-induced TNF factor
21: suppresses PTEN expression
107/103: modulates LDLRP-B (deleted in tumors), transforming growth factor-β
receptor III, fibroblast growth factor 2
122: modulates cholesterol and fatty acid synthesis
135a: modulates apoptosis inhibitor 5
200b: modulates LDLRP-B, insulin receptor substrate 1, tumor necrosis factor
receptor 11b (osteoprotegerin)
Abbreviations/symbols: (–), downregulated; (+), upregulated; LDLRP-B, low-density lipoprotein receptor-related protein-B; PGC-1α, peroxisome
proliferator-activated receptor-γ coactivator-1α; PTEN, phosphatase and tensin homolog.
aberrant miRNA expression profiles in primary
hepatocarcinoma (HCC) compared with nor-
mal liver tissue (8, 9) (Table 1). MiRNA-21
promotes hepatocyte invasion, migration, and
growth via repression of the tumor suppres-
sor phosphatase and tensin homolog (PTEN),
whose targeted deletion in murine hepatocytes
leads to the development of HCCs (10), and the
miRNAs 221–222 are associated with the out-
come of HCCs. Among miRNAs downregu-
lated in HCCs, miRNA-122 has received much
attention because it is expressed specifically in
the liver and accounts for 70% of the total
liver miRNAs. Among the validated targets of
miRNA-122, cyclin G1 and hepatitis C virus
(HCV) have significance in HCCs. Indeed, cy-
clin G1 levels are increased in HCCs, and
experimental models of hepatocarcinogenesis
demonstrated that loss of cyclin G1 is associated
with a significantly lower tumor incidence af-
ter carcinogen treatment, whereas HCV repre-
sents a predisposition factor for HCC. MiRNA-
122 binds to the 5′ noncoding region of the
HCV RNA genome, enhancing viral RNA
replication (11). Consistently, miRNA-122 is
downregulated in most of the mixed-etiology
HCCs but upregulated in HCV-related HCCs,
and interferon-β reduces hepatic miRNA-122
levels (12, 13).
The role of miRNAs in NAFLD is currently
being investigated, as well.
In human primary hepatocytes and in rats,
the addition of monounsaturated olive oil up-
regulated the expression of miRNA-21, which
bound to PTEN mRNA and induced its degra-
dation. This in turn led to PTEN downregu-
lation and hepatocyte fat infiltration (14). This
study provides evidence for dietary regulation
of miRNA-21 expression and may further link
dietary fat excess to different liver disorders,
given the emerging role of the tumor suppres-
sor PTEN in the pathogenesis of NAFLD,
NASH, and HCC (15).
Microarray and RT-PCR technology were
utilized to detect dysregulated miRNAs in
a rat model of NAFLD (16). Compared to
healthy animals, there were 58 miRNAs up-
regulated and 51 miRNAs downregulated in
NAFLD, most of which were differentially ex-
pressed in simple steatosis versus steatohep-
atitis. Putative target genes of dysregulated
miRNAs were involved in hepatocyte prolifer-
ation, apoptosis, inflammation, and glucose and
lipid metabolism (Table 1).
www.annualreviews.org • Nonalcoholic Fatty Liver Disease 377
A
nn
u.
 R
ev
. M
ed
. 2
01
0.
61
:3
75
-3
92
. D
ow
nl
oa
de
d 
fro
m
 ar
jou
rna
ls.
an
nu
alr
ev
iew
s.o
rg
by
 U
ni
ve
rs
ita
 d
eg
li 
St
ud
i D
i T
or
in
o 
- D
ep
ar
tm
en
t o
f P
la
nt
 B
io
lo
gy
 o
n 
02
/0
9/
10
. F
or
 p
er
so
na
l u
se
 o
nl
y.
AREV402-ME61-25 ARI 6 December 2009 8:29
FAS: fatty acid
synthase
GLP-1: glucagon-like
peptide-1
GIP: glucose-
dependent
insulinotropic
polypeptide
Finally, the hepatic expression profile of 474
miRNAs was assessed in patients with NASH.
Compared with healthy controls, 23 miRNAs
were differentially expressed in the liver of
NASH subjects (17). Opposite to mouse mod-
els, hepatocyte miRNA-122 expression was
63% lower in human NASH; reduced miRNA-
122 expression was associated with an increased
expression of several target miRNA-122 li-
pogenic genes, including fatty acid synthase
(FAS), 3-hydroxy-3-methyl-glutarylcoenzyme
A reductase (HMG-CoA reductase), and their
transcriptional activators, the sterol-response-
element binding proteins 1c and 2 (SREBP-
1c, SREBP-2). Intriguingly, in a subsequent ex-
periment with cultured human hepatocytes, in
vitro silencing and overexpression of miR-122
by reverse transfection were able to function-
ally modulate the expression of all these target
genes and proteins involved in lipid synthesis.
The clinical implications of these data are
twofold. First, the miRNA profile may serve
as a diagnostic and prognostic biomarker in
NAFLD, helping to noninvasively differentiate
simple steatosis, which has a benign course,
from progressive NASH, which can progress
to cirrhosis and end-stage liver disease. Second,
recent findings that antisense oligonucleotides
can selectively block specific miRNAs in vitro
and in vivo triggered efforts to explore miRNAs
as a potential new class of therapeutics. A recent
study demonstrated that intravenous injec-
tion of a short locked nucleic-acid-modified
oligonucleotide (“LNA-antimir”) could block
miR-122 activity in monkey, accompanied by
a dose-dependent and long-lasting lowering
of plasma cholesterol, without evidence of
toxicity or carcinogenity (18). A phase I safety
study in humans is ongoing. In high-fat-
fed mice, silencing miR-122 by a 20-OMe
phosphorothioate-modified antisense oligonu-
cleotide specific to miR-122 (“antagomir”)
resulted in a significant reduction of hepatic
steatosis, which was associated with reduced
cholesterol synthesis rates and stimulation of
hepatic fatty acid oxidation (19, 20). Con-
versely, restoring miRNA function by the
exogenous delivery of a synthetic miRNA
mimic might have therapeutic benefit where
tumor-suppressor miRNAs are underrepre-
sented; a recent study demonstrated that viral
delivery of let-7 inhibited tumor formation in
mouse models of lung cancer (21).
These encouraging data suggest a miRNA-
modulating strategy may prove an effective
therapeutic approach for many metabolic and
malignant diseases, including NASH. The up-
coming challenges are (a) to identify all targets
of deregulated miRNAs in these diseases and
assess which miRNAs or antimicroRNAs can
be used; (b) to ensure both the stability of the
modulators in the body and, most importantly,
delivery to, and uptake by, the organ or cells
of interest; and (c) last, but not least, to assess
carefully long-term safety of this approach.
INCRETIN
ANALOGS/ANTAGONISTS
Incretin mimetics have received much attention
in recent years because of their ability to stim-
ulate pancreatic β-cell insulin secretion and
growth, and they have been recently approved
for the treatment of diabetes. Different strate-
gies for enhancing incretin action have been
proposed. These agents include glucagon-like
peptide-1 (GLP-1) analogs, glucose-dependent
insulinotropic polypeptide (GIP) agonists, and
dipeptidyl peptidase-4 (DPP-4) inhibitors,
which inhibit the enzyme responsible for in-
cretin inactivation.
It is increasingly recognized GLP-1 and
GIP exert relevant extrahepatic actions that go
well beyond their antidiabetic action (reviewed
in 22) and may differentially affect their overall
metabolic effects (Table 2).
The rationale for employing GLP-1 analogs
in NAFLD lies in their weight-losing and in-
trahepatic effects (Table 2). Furthermore, re-
duced incretin action has been demonstrated
in nondiabetic nonobese patients with NASH
(23), thus prompting evaluation of GLP-1
analogs in fatty liver. In ob/ob mice, two months
of exendin-4 induced a dose-dependent weight
loss (7%–14% compared with placebo) and a
significant improvement in hepatic steatosis,
378 Musso · Gambino · Cassader
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Table 2 Similarities and differences between incretins GLP-1 and GIP
Characteristic GLP-1 GIP
Endocrine intestinal secreting cells L-cells (distal ileum, colon) K-cells (duodenum, jejunum)
Secretagogues Glucose, leptin, fatty acids, essential
amino acids, vagal stimulation
Glucose, fat (saturated > unsaturated)
Inhibitors of secretion Insulin, somatostatin, galanin
Plasma half-life of bioactive
molecule
2 min 5–7 min
Inactivating enzyme Serine protease dipeptidyl peptidase-4
(DPP-4)
DPP-4
Molecular mediators of biological
action in pancreas
AMP-activated PKA
PI-3K-activated PKC
cAMP-activated PKA
PI-3K-activated PKC
Pancreatic actions ↓ KATP channels activity ↓ KATP channels activity
↑ Glucose-dependent insulin secretion ↑ Glucose-dependent insulin secretion
↑ β-cell proliferation ↑ β-cell proliferation
↓ β-cell apoptosis ↓ β-cell apoptosis
↑ Somatostatin secretion
↓ Glucagon secretion
Central nervous system ↓ Appetite (hypothalamus) GIP receptors expressed in hippocampus;
unknown action
Gastrointestinal tract ↓ Gastric emptying and acid secretion ↓ Gastric acid secretion (supraphysiologic doses)
Net effect on body weight ↓ Neutral or slightly ↑
Circulating levels in diabetes ↓ Neutral or slightly ↑
Incretin effect in diabetes Preserved Blunted (receptor desensitization?)
Muscle ↑ Glucose uptake
↑ Glycogen synthesis
Liver ↑ Glycogen synthesis
↓ Gluconeogenesis
↑ Intracellular cAMP levels
↓ Glucagon-stimulated glucose production
(indirect mechanisms: no GIP receptors in
hepatocytes)
Adipose tissue ↑ Lipolysis
↑ Glucose uptake
↑ Lipogenesis (↑ fatty acid synthesis, uptake and
reesterification, ↑ LPL activity)
↑ Adiponectin secretion (94) ↓ Lipolysis
↑ Resistin/leptin secretion
Bone ? ↑ Osteoblast activity and bone remodeling
Kidney ↑ Natriuresis and diuresis ?
Abbreviations: cAMP, cyclic adenosine-monophosphate; PKA, protein kinase A; PKC, protein kinase C; LPL, lipoprotein lipase; PI-3K, phosphoinositide
3-kinase.
insulin sensitivity, and plasma adipokine pro-
file. These changes were associated with a
marked increase in hepatocyte cAMP produc-
tion and fatty acid oxidative pathways and with
a decrease in hepatic lipogenesis and oxida-
tive stress (24). In humans, Tushuizen et al.
reported a 3.6-fold reduction in liver fat follow-
ing 44 weeks of exenatide therapy in a diabetic
man (25). In an open-label extension of three
randomized placebo-controlled trials enrolling
217 overweight diabetic subjects, exenatide for
three years was safe and well-tolerated, and it
achieved a mean 5.3-kg weight loss as well as
a significant reduction of serum transaminases,
normalizing ALT levels in 41% of patients (26).
Although these data suggest a possible
role for GLP-1 agonists in the treatment of
NAFLD, preclinical evidence suggests GIP
may promote obesity-associated metabolic dis-
orders (27). GIP operates as a key modulator
www.annualreviews.org • Nonalcoholic Fatty Liver Disease 379
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FFA: free fatty acid
of lipid metabolism by stimulating glucose
uptake, lipoprotein lipase activity, free fatty
acid (FFA) synthesis, and incorporation in
adipocytes (28). Furthermore, GIP administra-
tion stimulated resistin and leptin secretion in
cultured adipocytes, an effect totally prevented
by knocking out GIP receptor (29, 30). Con-
sistent with these findings, acute and chronic
administration of GIP, but not of GLP-1, in-
duced fatty liver and other obesity-associated
metabolic disorders in mice, whereas GIP an-
tagonism reversed liver, muscle, and adipose tis-
sue fat infiltration and ameliorated associated
metabolic disturbances induced by high-fat diet
in mice (31, 32).
Dietary fat is the most potent stimulator of
GIP secretion. Saturated fat exerts higher stim-
ulatory effects than unsaturated fat, and exces-
sive saturated fat intake predisposes to diabetes,
cardiovascular disease, and liver fat infiltration
(33–37). Together these data suggest GIP may
mediate the deleterious metabolic effects of
a high-fat diet and may modulate adipocyte
adipokine secretion, independently of its in-
cretin effect on β-cell function (38).
Consistent with preclinical data, plasma GIP
response to fat ingestion is exaggerated in non-
diabetic nonobese patients with NASH and is
associated with reduced β-cell function and in-
cretin effect, as well as an unfavorable lipopro-
tein and adipokine profile (39). These findings
suggest GIP may be an important mediator of
the adipocyte response to nutritional excess,
through molecular mechanisms still largely un-
defined, and may in part account for the in-
creased metabolic risk of NAFLD.
The differential metabolic actions of GIP
agonists, GLP-1 analogs, and DPP-4 inhibitors
have been assessed in high-fat-fed mice, where
the three classes of agents exerted different
effects on β-cell function, insulin sensitiv-
ity, body weight, and adipokine levels. GLP-
1 analog exendin-4 reduced food intake, and
both exendin-4 and DPP-4 inhibitor prevented
weight gain and ameliorated glucose toler-
ance and insulin sensitivity; GIP agonism did
not prevent weight gain and was associated
with worsened insulin sensitivity, increased
circulating leptin and resistin, and a less pro-
nounced improvement in glucose tolerance
(40).
Therapeutically, as incretin analogs are eval-
uated in NAFLD, the relative merits of inhibi-
tion versus activation of GIP signaling should
be considered. Specifically, while circulating
levels of GLP-1 are reduced and pancreatic
sensitivity to its incretin actions is preserved
in obesity and diabetes, GIP has lost most of
its insulin-stimulatory action, and its noxious
extrapancreatic effects may offset the benefit
of a blunted incretin effect. Although GLP-1-
agonists may be potentially effective and harm-
less, the benefits of GIP antagonism may over-
come ablation of the insulin-releasing GIP
component of the entero-insular axis, which is
already failing in obesity and diabetes; therefore
a strategy with mixed GLP-1 agonism and GIP
antagonism may be more effective for the treat-
ment of NAFLD and obesity-related disorders
(27).
LIVER-SPECIFIC
THYROMIMETICS
The antiobesity and low-density lipoprotein
(LDL)–cholesterol–lowering effects of thyroid
hormones have been known for years, but their
pharmacological use has been limited by their
untoward effects on bone and heart and skele-
tal muscle. Recent research has developed drugs
that lack these adverse effects and harness the
beneficial effects of thyroid hormone. The de-
velopment of these drugs, termed thyromimet-
ics, was made possible by the existence of
distinct thyroid hormone receptor (TR) sub-
types with different tissue-specific distribution
(41). There are two subtypes of TRs, TRα
and TRβ, predominantly localized in the heart
and liver, respectively. Splice variants of each
gene generate different TR isoforms, four of
which (TRα1, TRα2, TRβ1, and TRβ2) are
expressed at the protein level in vivo (42).
Selective TRβ1 agonists have been synthe-
sized and evaluated in preclinical trials and in a
short clinical trial, showing their lipid-lowering
properties and safety (43). The liver specificity
380 Musso · Gambino · Cassader
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of these drugs is achieved through the selec-
tive hepatic distribution of phosphonic acid: A
phosphonate-containing TRβ1 agonist is taken
up predominantly by the liver with a high first-
pass extraction and converted into the active
form in hepatic microsomes by cytochrome
P450 3A.
Recently, the main compound of this type,
MB07811, has been evaluated in different
animal models of hepatic steatosis, including
ob/ob mice, Zucker diabetic rats, and mice
with diet-induced obesity (44). At the end
of treatment, liver triglyceride content was
reduced by >66% in both normal and obese
animals. A marked reduction was also observed
in plasma cholesterol and triglyceride levels.
Hepatic selectivity of MB07811 was demon-
strated by showing that this agent did not affect
circulating FFA levels, epidydimal fat pad and
heart mass, or pituitary thyroid-stimulating
hormone mRNA. Intrahepatic mechanisms of
action of MB07811 included an increased rate
of mitochondrial β-oxidation, as assessed by
(a) an increase in the mRNA levels of carnitine
palmitoyltransferase-1 (CPT-1), a rate-limiting
enzyme in the fatty acid oxidation cycle; (b) el-
evated levels of short and intermediate-length
acyl-carnitine species in plasma; (c) increased
mitochondrial respiration rates observed in
ex vivo liver preparations; and (d ) increased
activity of hepatic mitochondrial glycerol-
3-phosphate dehydrogenase (mGPDH), an
enzyme involved in energy production and dis-
sipation. A decrease in hepatic lipogenesis, as
suggested by a reduction in SREBP-1c mRNA,
and in hepatic lipase activity, as suggested by
reduced levels of apolipoprotein C3 (apoC3, an
inhibitor of lipoprotein lipase), might also con-
tribute to the antisteatotic effects of this agent.
These findings were independently reproduced
by Perra et al. in choline-methionine-deficient
(CMD) rat, an animal model of nutritional
steatohepatitis (45). Importantly, in this study
GC-1, another TRβ1-selective activator,
ameliorated not only steatosis but also markers
of hepatic lipoperoxidation and liver injury,
suggesting these agents have the potential to
reverse not only fat infiltration but also the
AMPK: adenyl
monophosphate–
activated protein
kinase
progressive features of steatohepatitis. How
TR mimetics can ameliorate hepatocyte ox-
idative stress and necroinflammation warrants
further investigation. It has been proposed
that T3 agonists generate “futile” cycles,
including the glucose-6-phosphate cycle, the
pyruvate/malate and pyruvate/citrate shuttles,
the pentose-phosphate cycle, and the fructose-
6-phosphate/1,6-diphosphate cycles. These
futile cycles reduce oxidative stress in two ways:
They increase ATP cycling, which enhances
oxidative phosphorylation and decreases the
formation of reactive oxygen species (ROS);
and they supply the NADPH necessary for the
regeneration of reduced glutathione (GSH)
and other reducing substances, thus facilitating
the scavenging of ROS (46).
Collectively, the results of these studies show
promise for the treatment of NAFLD and as-
sociated metabolic disorders, but efficacy and
safety of this class of agents in humans need
further evaluation.
AMP-ACTIVATED
PROTEIN KINASE
The discovery that many of the beneficial
effects of metformin, physical exercise, caloric
restriction, leptin, and adiponectin-mediated
actions of thiazolidinediones converge on
the enzyme AMP-activated protein kinase
(AMPK) has renewed interest in the modula-
tion of the activity of this kinase (see sidebar
Structure and Molecular Activators of AMPK).
Pharmacological AMPK activators are being
developed for the treatment of multiple
metabolic disorders, including NAFLD (47).
Regulation of AMPK activity involves both
direct allosteric activation by AMP and re-
versible phosphorylation of AMPKα subunit
on Thr172 by upstream kinases. The combi-
nation of the allosteric and phosphorylation ef-
fects amplifies kinase activity by >1000-fold,
allowing a fine integrated sensing of cellular
metabolism in response to small changes in en-
ergy status. Under conditions of high energy
demand, intracellular ATP is reduced, AMP
rises, and the AMP/ATP ratio provides a very
www.annualreviews.org • Nonalcoholic Fatty Liver Disease 381
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STRUCTURE AND MOLECULAR ACTIVATORS
OF AMPK
AMPK is a heterotrimeric serine/threonine kinase composed of
a catalytic α subunit and regulatory β and γ subunits. Multiple
genes encode the three subunits (α1, α2, β1, β2, γ1, γ2, γ3), al-
lowing 12 heterotrimeric combinations, with splice variants. Of
the 12 theoretically possible complexes only 3 were detected in
human skeletal muscle (α2β2γ1  α2β2γ3 = α1β2γ1). Ser-
ine/threonine kinase activity of AMPK is possessed by α sub-
units, which contain a threonine residue (Thr172) whose phos-
phorylation is required for AMPK activation. The β subunits
contain a C-terminal region required for the association with α
and γ subunits and a central region that allows AMPK com-
plex to bind glycogen, which explains the tight regulation of
glycogen metabolism by AMPK. The γ subunits contain four
tandem repeats, known as the cystathionine β-synthase (CBS)
motif, which bind two molecules of AMP or ATP in a mutually
exclusive manner. Binding of AMP (on the γ subunit) activates
AMPK allosterically and promotes phosphorylation of theα sub-
unit (on Thr172) by upstream kinases as protein kinase LKB1
or the CaMKKβ (calmodulin-dependent protein kinase kinase).
AMP binding also inhibits Thr172 dephosphorylation by protein
phosphatase, while binding of ATP strongly inhibits the activa-
tion of AMPK.
sensitive indication of cellular energy balance
(48).
In the latest years, there has been in-
creased interest in developing drugs that mimic
the benefits of calorie restriction and physi-
cal exercise, which are the mainstay treatment
for metabolic disorders but often cannot be
achieved or maintained. Preclinical studies as-
sessed the effects of pharmacological activation
of AMPK on different organs and functions;
the compound AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribonucleoside), metabo-
lized to ZMP, which is an analog of AMP,
has been most extensively tested. In nor-
mal and insulin-resistant obese rats, infusion
of AICAR suppressed hepatic glucose pro-
duction, mostly through the phosphorylation
and inactivation of a transcriptional coacti-
vator, transducer of regulated CREB activ-
ity 2 (TORC2) (49, 50). TORC2 mediates
CREB-dependent transcription of peroxisome-
proliferator-activated receptor-γ coactivator
1α (PGC-1α) and its gluconeogenic enzymes
phosphoenolpyruvate carboxykinase (PEPCK)
and glucose-6-phosphatase (G6Pase).
Reduced hepatic glucose output was cou-
pled with enhanced glucose disposal by skeletal
muscle, which was mediated by increased
translocation of glucose transporter GLUT4
to cell membranes, enhanced mitochondrial
biogenesis, and enhanced glucose oxidation.
These effects occur through a different mech-
anism than the insulin-signaling pathway,
involving the phosphorylation of TBC1D1, a
Rab-GTPase-activating protein that regulates
the translocation of GLUT4 from intracellular
vesicles to the plasma membrane by maintain-
ing G-proteins named Rab in a GDP-bound
state. The phosphorylation and subsequent
inactivation of TBC1D1 allow the release and
translocation of GLUT4 from the vesicle (51).
Besides glucose homeostasis, AMPK also
regulates hepatic lipid metabolism. Its activa-
tion by AICAR, alpha-lipoic acid, or oltipraz
has been shown to decrease liver fat content in
lean and obese rodents (52–54). These effects
were mediated by a direct phosphorylation and
inactivation of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-CoA reductase)
and acetyl-CoA carboxylase (ACC), key
enzymes in hepatic cholesterol and fatty
acid synthesis, and by inhibition of SREBP-
1c-mediated transcription of key lipogenic
enzymes, including fatty acid synthase, ACC,
stearoyl-CoA desaturase-1, and ATP-binding
cassette transporter A1 (55). Inhibition of
ACC by AMPK leads to a fall in malonyl-CoA
levels and subsequently removes the inhibi-
tion to mitochondrial fatty acid β-oxidation,
eventually reducing excessive storage of
triglycerides. Furthermore, AMPK activation
directly leads to a significant activation of
PGC-1α-mediated mitochondrial biogenesis,
increasing mitochondrial number and enzymes
in hepatocytes (56).
Other effects of AMPK activators include
central appetite regulation, myocardial precon-
ditioning and protection against ischemia and
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Table 3 Activators, molecular mediators, and effects of AMP kinase in different tissues and organs
Activators Tissue Molecular target Effect
Physical exercise Skeletal muscle ↑ GLUT-4 translocation ↑ Glucose uptake and oxidation
Starvation ↑ Hexokinase II ↑ Insulin sensitivity
Biguanides, TZD
(adiponectin-mediated)
↑ PGC-1α-mediated
mitochondrial biogenesis (97)
Adiponectin
Leptin
Liver ↑ Phosphorylation of HMG-CoA
reductase/PK/ACC
↓ Glucose production
↓ Lipogenesis and cholesterol synthesis
Ghrelin
AICAR
Thienopyridones
↓ SREBP-1c-mediated lipogenesis
↑ PGC-1α-mediated
mitochondrial biogenesis
↑ Mitochondrial biogenesis and fatty acid
β-oxidation
Dithiolethiones (oltipraz)
Alpha-lipoic acid
Heart ↑ Glucose utilization
↓ Myocyte hypertrophy
Protects myocytes against ischemia
(ischemic preconditioning)
Polyphenols (95, 96) ↓ Cardiac hypertrophy
Endothelium ↑ Endothelial NOS activity ↑ Endothelial function
Pancreatic β-cell ↑ Fatty acid and glucose oxidation ↓ Glucolipotoxicity
↓ Insulin release by β-cell
hyperpolarization
Spares β-cell function
Hypothalamus ↑ Neuropeptide Y ↑ Appetite
↑ Agouti-related peptide (AgRP)
↑ Mitochondrial fatty acid
β-oxidation
Abbreviations: AICAR, 5-amino-imidazole-4-carboxamide ribonucleoside; SREBP-1c, sterol regulatory element binding protein-1c; PGC-1α,
peroxisome proliferator-activated receptor-γ coactivator-1α; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; PK, pyruvate
kinase; ACC, acetyl-CoA carboxylase.
hypertrophy (57–59), and endothelial function
improvement through nitric-oxide-synthase-
dependent and -independent mechanisms (60).
The benefits of AMPK activators on β-cell
function are less well established (61,
Table 3).
It is worth noting that the effects of AMPK
activators are insulin independent and thus pre-
served in insulin-resistant-diabetic and obese
subjects, such as those with NAFLD. These en-
couraging preclinical data need confirmation in
human trials. The effects of AMPK activators
on hepatic cellular mechanisms, other than li-
pogenesis, involved in necroinflammation and
fibrogenesis are currently unknown, and such
effects are crucial for the treatment of pro-
gressive NASH. In this context, AICAR infu-
sion significantly reduced hepatic glucose out-
put and whole-body lipolysis, decreasing blood
glucose and FFA levels in a small group of dia-
betic subjects (62).
NUCLEAR TRANSCRIPTION
FACTORS: FARNESOID X
RECEPTOR
Originally described as a farnesol-activated re-
ceptor, farnesoid X receptor (FXR) has been
long known for its function of bile acid sensor
in enterohepatic tissues (63). FXR has emerged
in recent years as a master regulator of lipid
and glucose homeostasis and of inflammatory
processes at hepatic and extrahepatic sites, and
a number of synthetic FXR agonists are being
tested for the treatment of different hepatic and
metabolic disorders (64, 65).
Two FXR genes have been identified,
FXRα and FXRβ. FXRα encodes four isoforms
(FXRα1, FXRα2, FXRα3, and FXRα4) as a re-
sult of the use of alternative-RNA splicing.
FXRα is expressed mainly in the liver, intes-
tine, kidney, and adrenal glands, and at much
lower levels in adipose tissues. The second FXR
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gene, FXRβ, is a lanosterol sensor that en-
codes a functional protein in rodents but not in
humans.
FXR is an obligate partner of the 9-
cis-retinoic acid receptor RXR (retinoid X
receptor). The FXR/RXR heterodimer mod-
ulates gene expression through binding to
specific DNA sequences called FXR response
elements. Upon ligand binding, FXR un-
dergoes conformational changes to release
corepressors such as nuclear corepressor
and recruit coactivators such as PGC-1α,
CARM-1 (coactivator-associated arginine
methyltransferase-1), DRIP-205 (vitamin-
D-receptor-interacting protein-205), SRC-1
(steroid receptor coactivator-1), and PRMT-1
(protein arginine methyl transferase-1) (66). It
is unclear how these coactivators are recruited
by FXR ligands and how they are involved in
specific gene regulation by FXR ligands.
The relevance of FXR to hepatic physi-
ology and disease is known from the obser-
vation that FXR-deleted mice on a high-fat
diet exhibit hyperlipidemia and massive hep-
atic steatosis, as well as necroinflammation and
fibrogenesis (67, 68). Importantly, when mice
knocked-out for LDL receptor (LDLR) and
FXR were challenged with fat, high fat led to
macrosteatosis without inflammation in the liv-
ers of LDLR−/−/FXR+/+ mice, whereas the
livers of double-knockout (LDLR−/−/FXR−/−)
mice showed necroinflammation and increased
hepatic levels of tumor necrosis factor-α, in-
tercellular adhesion molecule-1, transforming
growth factor (TGF)–β, procollagen 1α1 and
collagen, suggesting FXR may prevent progres-
sion of simple steatosis to NASH.
The molecular basis for these actions is be-
ing unraveled. FXR induces expression of genes
that promote triglyceride clearance and mito-
chondrial fatty acid β-oxidation, together with
a suppression of lipogenic gene transcription
(69). Furthermore, small heterodimer partner
(SHP), a nuclear receptor with corepressor ac-
tivity that is strongly induced by FXR, interferes
with SREBP-1c expression by inhibiting the
activity of the liver X receptor, further reducing
hepatic lipogenesis (70). FXR also upregulates
the genes encoding apolipoprotein C-II
(apoC-II) and very-low-density lipoprotein
receptor, therefore enhancing triglyceride-rich
lipoprotein clearance, while apoA-I gene
expression is repressed (71). The latter action
may explain the high-density-lipoprotein
(HDL) cholesterol reduction observed in
patients on bile acid supplementation, and the
specular increase in apoA-I and HDL choles-
terol levels in subjects after ileal resection or
on cholestyramine (72).
FXR regulates glucose homeostasis as well.
In mice, FXR deletion promotes insulin re-
sistance in both muscle and liver, leading to
impaired glucose tolerance and hyperglycemia.
Synthetic FXR agonists decrease gluconeoge-
nesis in mice fed a high-fat diet by reduc-
ing the expression and activity of PEPCK,
G6Pase, and fructose-1,6-biphosphatase, and
by enhancing insulin signaling through insulin-
receptor substrate-1 (IRS-1) phosphorylation
(73, 74).
In addition to its effects on glucose and
lipid homeostasis, FXR appears to antago-
nize hepatic inflammatory and fibrogenetic
processes. FXR agonists have been recently
shown to antagonize nuclear factor (NF)–κB
pathway activation in primary hepatocytes
and in rodents challenged with bacterial
lipopolysaccharide (LPS) (75). FXR−/− livers
showed massive necroinflammation after treat-
ment with LPS at a dose that did not induce
significant liver damage in wild-type mice,
whereas FXR activation suppressed NF-κB-
mediated expression of inducible nitric oxide
synthase (iNOS), cyclooxygenase-2 (COX-2),
interferon-γ-inducible protein-10 (IP-10), and
interferon-γ (IFN-γ) induced by LPS adminis-
tration. Another hepatic protective mechanism
of FXR activation against gut-derived endo-
toxins is represented by the maintenance of
gut integrity through induction of antibac-
terial factors such as angiogenin, iNOS, and
interleukin (IL)–18 (76). FXR also possesses
antifibrotic properties. Synthetic FXR agonist
6-ethyl chenodeoxycholic acid (6-ECDCA)
reduced the expression of the profibrotic genes
encoding collagen α(1)I, α-smooth muscle
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actin, tissue inhibitors of metalloproteinase 1
and 2, and TGF-β1 in cultured hepatic stellate
cells. 6-ECDCA also reversed hepatic fibrosis
in several rat models of liver injury (77, 78).
NUCLEAR TRANSCRIPTION
FACTORS: PREGNANE X
RECEPTOR
The pregnane X receptor (PXR) was initially
identified as a nuclear receptor regulating xeno-
biotic and drug metabolism and elimination
(79). Upon activation by a variety of ligands in-
cluding drugs, insecticides, pesticides, and nu-
tritional compounds, PXR forms a heterodimer
with RXR that binds to PXR response elements,
located in the 5′-flanking regions of target
genes, resulting in their transcriptional activa-
tion.This “xenosensor” coordinates the expres-
sion of several genes encoding the most impor-
tant xenobiotic metabolizing and transporting
system, to inactivate and eliminate these com-
pounds through four phases: uptake; oxidation
(mostly through cytochrome P450 3A and
2B); conjugation by uridine-50-diphosphate
glucuronosyltransferases (UGT), glutathione
S-transferases (GST), or sulfono-transferases;
and efflux, performed by transporters like
multidrug resistance protein-1 (MDR1) (80).
It subsequently became clear that this system
was also involved in catabolism of bile acid,
bilirubin, and thyroid and steroid hormone,
affecting their kinetics (81) (Tables 4 and 5).
Subsequent functional studies using PXR
knockout and transgenic mice have implicated
PXR in hepatic steatosis and carbohydrate
and lipid homeostasis. Transgenic mice overex-
pressing the activated human PXR in the liver
displayed marked hepatic triglyceride accumu-
lation compared to the wild type (82). The
lipogenic effect of PXR was independent of
SREBP-1c and its primary target enzymes FAS
and ACC-1. This effect occurred at 3 levels (83):
1. Enhanced de novo lipogenesis. PXR
activation directly enhanced transcrip-
tion of lipogenic enzymes stearoyl-
CoA desaturase-1 (SCD-1) and fatty
acid elongase (FAE). Furthermore, PXR
enhanced transcription of lipogenic en-
zymes FAS and ATP citrate lyase (ACLY)
by interacting with the thyroid-hormone-
responsive SPOT14 homolog S14, a
transcription regulator that is emerging
as a key stimulator of lipogenesis induced
by carbohydrate feeding and thyroid hor-
mone administration (84).
2. Enhanced hepatocyte uptake of cir-
culating FFA by the membrane fatty
acid translocase fatty acid transporter
(FAT)/CD36. Analysis of the mouse
CD36 gene promoter revealed that CD36
is a direct transcriptional target of PXR.
This regulation is achieved by binding of
the PXR-RXR heterodimers to a PXR re-
sponse element found in the CD36 gene
promoter. Interestingly, the regulation of
CD36 by PXR is liver specific. The same
study found that activation of PXR also
induced the expression of PPARγ, an-
other positive regulator of CD36, sug-
gesting that PXR can upregulate CD36
directly or indirectly through activation
of PPARγ (82).
3. Downregulation of several genes in-
volved in β-oxidation, including PPARα
and thiolase (82–85). The notion that ac-
tivation of PXR may suppressβ-oxidation
and influence lipogenesis was supported
by a recent study by Nakamura et al. (86).
These authors showed that treatment
with PXR agonist pregnenolone-16α-
carbonitrile (PCN) downregulated
transcription of the genes encod-
ing carnitine palmitoyltransferase 1a
(CPT1a) and mitochondrial 3-hydroxy-
3-methylglutarate-CoA synthase 2
(Hmgcs2) in the liver of fasting wild-
type, but not PXR-null, mice (87).
CPT1a is a key regulatory factor in
insulin-dependent repression of β-
oxidation, and Hmgcs2 is an enzyme
important for ketogenesis. The SCD-1
mRNA was also found to be upregu-
lated in PCN-treated wild-type mice,
contributing to hepatic fatty infiltration.
Consistent with the pattern of gene
www.annualreviews.org • Nonalcoholic Fatty Liver Disease 385
A
nn
u.
 R
ev
. M
ed
. 2
01
0.
61
:3
75
-3
92
. D
ow
nl
oa
de
d 
fro
m
 ar
jou
rna
ls.
an
nu
alr
ev
iew
s.o
rg
by
 U
ni
ve
rs
ita
 d
eg
li 
St
ud
i D
i T
or
in
o 
- D
ep
ar
tm
en
t o
f P
la
nt
 B
io
lo
gy
 o
n 
02
/0
9/
10
. F
or
 p
er
so
na
l u
se
 o
nl
y.
AREV402-ME61-25 ARI 6 December 2009 8:29
Table 4 Molecular mechanisms of action of farnesoid X receptor
Activators Molecular mechanisms Effects
Bile acids (chenodeoxycholic acid)
PUFA (arachidonic, linolenic, or
docosahexaenoic)
↓ Expression of SREBP-1c and its lipogenic
target genes (SHP-dependent and
-independent mechanisms)
↓ Liver fat
↓ VLDL secretion and enhances its catabolism,
thereby reducing plasma triglyceride levels
Synthetic agonists (GW4064,
6-ECDCA, fexaramine) (98)
↑ Transcription of enzymes involved in fatty
acid β-oxidation through PPAR-α activation
↓ Synthesis and uptake of HDL-C, with a net
reduction in HDL-C levels
↓ ApoC-III and apoA-1 synthesis
↓ Hepatic lipase activity
↑ ApoC-II synthesis and VLDL-receptor
expression
↓ Hepatic expression of gluconeogenetic
enzymes PEPCK, G6-Pase and
fructose-1,6-biphosphatase
↓ Hepatic gluconeogenesis
↑ Hepatic insulin sensitivity
↑ IRS-1 phosphorylation and coupling with
the PI-3K activity
↓ NF-κB-mediated activation of
inflammation
↓ NF-κB-mediated expression of iNOS,
COX-2, IP-10, and IFN-γ
↑ Intestinal expression of antibacterial factors
such as angiogenin, iNOS, and IL-18
Maintains gut integrity and impermeability to
bacterial endotoxins
↓ Hepatic stellate cell expression of: collagen
α(1)I, α-smooth muscle actin, tissue
inhibitors of metalloproteinase 1 and 2, and
TGF-β1 genes
↓ Hepatic fibrogenesis
Abbreviations: PUFA, polyunsaturated fatty acid; 6-ECDCA, 6-ethyl chenodeoxycholic acid; SREBP-1c, sterol-response-element binding protein 1c;
SHP, small heterodimer partner; VLDL, very-low-density lipoprotein; HDL, high-density lipoprotein; PPAR, peroxisome-proliferator-activated
receptor; iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor κB; TGF-β1, transforming growth factor β1; COX-2, cyclooxygenase-2; IP-10,
interferon-γ-inducible protein 10; PEPCK, phosphoenol-pyruvate carboxykinase; IRS-1, insulin-receptor substrate-1; PI-3K, phosphoinositide 3-kinase.
Table 5 Molecular mechanisms of action of pregnane X receptor
Activators Molecular mechanisms Effects
5α-pregnane-3,20-dione,
progesterone,
17α-hydoxyprogesterone,
17α-hydroxypregnenolone and
corticosterone, dexamethasone
↑ Transcription of lipogenic enzymes SCD-1 and fatty
acid elongase
↑ Transcription of lipogenic enzymes FAS and ATP
citrate lyase (S14-mediated)
↑ Hepatocyte FFA uptake from plasma by FAT/CD36
↑ De novo fatty acid synthesis and
uptake from plasma
↓ Mitochondrial fatty acid
oxidation
Antiglucocorticoids (pregnenolone-
16α-carbonitrile, RU486)
Tamoxifen
↓ Carnitine palmitoyltransferase 1A (CPT1a),
↓PPAR-α activation
↓ Glucogenesis
Taxol
Anti-infective chemotherapies
(rifampicin, ritonavir, clotrimazole)
↓ Hepatic expression of PEPCK and G6-Pase
(HNF-4/PGC-1α-mediated)
↓ Hepatic FOXO1 transcription
↓ Hepatic gluconeogenesis
Organochlorine pesticides ↓ Hepatic stellate cell transdifferentiation,
proliferation and fibrogenetic activity
↓ Hepatic fibrogenesis
Abbreviations: SCD-1, stearoyl-CoA desaturase-1; FFA, free fatty acid; FAS, fatty acid synthase; FAT, fatty acid transporter; HNF-4, hepatocyte nuclear
factor-4; PGC-1α, PPARγ coactivator 1α; FOXO1, forkhead box–containing protein O subfamily-1.
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regulation, the levels of hepatic triglyc-
erides were increased and levels of serum
3-hydroxybutyrate were decreased in the
PCN-treated wild-type mice. The same
study showed that PXR could cross-talk
with the insulin-responsive forkhead fac-
tor FoxA2 to suppress the transcription
of the CPT1a and Hmgcs2 genes. The
authors concluded that activation of PXR
represses FoxA2-mediated transcription
of CPT1a and Hmgcs2 genes in fasting
liver.
PXR suppresses hepatic gluconeogenesis
by competing with hepatocyte nuclear factor-4
(HNF-4) for the binding of PPARγ coactivator-
1α (PGC-1α), thus attenuating HNF-4
signaling (88). The HNF-4/PGC-1α pathway
plays a central role in regulating glucose/energy
metabolism by regulating the gluconeogenic
G6-Pase and PEPCK genes (89). PXR also
acts as a corepressor of the transcription
factor forkhead box–containing protein O
subfamily-1 (FOXO1), another stimulator of
gluconeogenesis. FOXO1 overexpression in
NASH correlated with the severity of hepatic
necoinflammation and insulin resistance (90,
91).
Besides regulating lipid metabolism, PXR
has been proposed as a potential target for
antifibrotic therapy. In a rat model of car-
bon tetrachloride-induced injury, hepatocyte
necrosis and liver fibrosis were significantly
inhibited by PXR agonists (92). These effects
were replicated in cultured human primary
hepatic stellate cells, where the PXR ligand
rifampicin inhibited the expression of fibro-
genetic genes and reduced the proliferation
and transdifferentiation to a profibrogenic
phenotype of hepatic stellate cells. All of
these effects were PXR dependent (93). The
balance between the steatogenic and the
antigluconeogenetic and antifibrotic effects of
PXR activation must be weighed in a clinical
model before any conclusion can drawn on the
efficacy/safety profile of PXR antagonists as
antifibrotic therapy.
SUMMARY AND FUTURE
DIRECTIONS
With the growing epidemic of obesity, the
prevalence of NAFLD will grow exponentially
in the next 10 years. In the absence of an
effective therapy, NASH is projected to be the
leading cause of cirrhosis and liver transplanta-
tion by 2020. Ongoing research faces every as-
pect of the putative pathogenetic mechanisms
of NAFLD, from insulin resistance to dysreg-
ulated hepatic lipid and glucose metabolism to
increased hepatic inflammation and fibrogene-
sis. Ongoing research targets molecular mech-
anisms at the crossroads of multiple abnormal-
ities accompanying NAFLD: hepatic glucose
and triglyceride dysmetabolism, liver fat infil-
tration, inflammation, and fibrosis. As of May
2009, results of preclinical studies are encour-
aging. Two main challenges remain for the fu-
ture: translating cellular/animal models to hu-
man pathology and testing the long-term safety
and efficacy of those treatments that prove ef-
fective in preclinical trials.
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